Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2019

01-07-2019 | Research Article

Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review

Authors: Anders Kindberg Boysen, Jakob Vasehus Schou, Karen-Lise Garm Spindler

Published in: Clinical and Translational Oncology | Issue 7/2019

Login to get access

Abstract

Background

Preoperative chemoradiotherapy is the standard of care for patients with locally advanced rectal cancer, yet valid circulating biomarkers are lacking. We aimed at systematically reviewing the literature of cell-free DNA and locally advanced rectal cancer.

Methods

A systematic literature search was performed. We retrieved papers reporting a correlation between a clinical outcome and cell-free DNA for patients receiving chemoradiotherapy for locally advanced rectal cancer.

Results

We included nine studies of a total of 615 patients. Only single-arm studies were identified, analyzing either the total level of cell-free DNA or tumor-specific DNA. Despite differences in the methodology and outcomes, eight of the nine studies showed a correlation between cell-free DNA and a clinical outcome.

Conclusions

Cell-free DNA might hold prognostic and predictive information for patients with locally advanced rectal cancer receiving preoperative chemoradiotherapy; although, firm conclusions are limited by the heterogeneity in this field.
Literature
1.
Giovannucci E, Wu K. Cancers of the colon and rectum. In: Schottenfeld D, Fraumeni J, editors. Cancer. Epidemiology and prevention. 3rd ed. Oxford: Oxford University Press; 2006.
2.
Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–40.CrossRefPubMed
3.
Kapiteijn E, Marijnen C, Nagtegaal I, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.CrossRefPubMed
4.
Ngan S, Burmeister B, Fisher R, et al. Randomized trial of short course radiotherapy versus long course chemoradiation comparing rates of local recurrence in patients with T4 rectal cancer: Trans Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol. 2012;30:3827–33.CrossRefPubMed
5.
Leichman C, McDonough S, Smalley S, et al. Cetuximab combined with induction oxaliplatin and capecitabine, followed by neoadjuvant chemoradiation for locally advanced rectal cancer: SWOG 0713. Clin Colorectal Cancer. 2017;17:e121–5.CrossRefPubMedPubMedCentral
6.
Appelt A, Pløen J, Harling H, et al. High dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27.CrossRefPubMed
7.
Brown G, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathological comparison. Radiology. 2003;227(2):371–7.CrossRefPubMed
8.
Dayde D, Tanaka I, Tai M, et al. Predictive and Prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci. 2017;18:573.CrossRefPubMedCentral
9.
Mandel P, Metasis P. Les acides nucleiques du plasma sanguis chez l’homme. CR Seances Soc Biol Fil. 1948;142:241–3.
10.
Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of patients and the effect of therapy. Cancer Res. 1977;37:646–50.PubMed
11.
Spindler KL, Boysen AK, Pallisgaard N, et al. Cell free DNA in metastatic colorectal cancer—a systematic review and meta analysis. Oncologist. 2017;22(9):1049–55.CrossRefPubMedPubMedCentral
12.
Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;151(4):264–9.
13.
Whitting PF, Rutjes A, Westwood M, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRef
14.
Zitt M, Muller H, Rochel M, et al. Circulating cell free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers. 2008;25(3):159–65.CrossRefPubMedPubMedCentral
15.
Agostine M, Pucciarelli S, Vittoria M, et al. Circulating cell free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiation. Ann Surg Oncol. 2011;18:2461–8.CrossRef
16.
Sun W, Sun Y, Zhu M, et al. The role of plasma cell free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. Oncol Rep. 2014;31:1466–72.CrossRefPubMed
17.
Carpinetti P, Donnard E, Bettoni F, et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. 2015;6(35):38360–71.CrossRefPubMedPubMedCentral
18.
Boysen AK, Wettergren Y, Sørensen BS, et al. Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. Tumor Biol. 2017;39(11):1–6.CrossRef
19.
Schou JV, Larsen FO, Sørensen BS, et al. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer. Ann Oncol. 2018;0:1–6.
20.
21.
Tie J, Cohen J, Wang Y, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2018;0:1–9.
22.
Li M, Xiao W, Zhao G, et al. Predictive value of circulating tumor DNA in locally advanced rectal cancer patients receiving neoadjuvant radiochemotherapy. J Clin Oncol. 2017;35:n15_supplement.
23.
Ryan JE, Warrier SK, Lynch AC, et al. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2015;17:849–61.CrossRefPubMed
24.
Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28((Supplement 4)):iv22–40.CrossRefPubMed
25.
Negri FV, Campanini N, Camisa R, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer. 2008;98:143–7.CrossRefPubMed
26.
Sturm I, Rau B, Schlag PM, et al. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMC Cancer. 2006;6:124.CrossRefPubMedPubMedCentral
27.
Spindler KL, Nielsen JN, Lindebjerg J, et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys. 2006;66:500–4.CrossRefPubMed
28.
Hur H, Kim NK, Min B, et al. Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiothreapy for rectal cancer? Dis Colon Rectum. 2014;57:5.CrossRef
29.
Probst C, Beccera A, Acuina C, et al. Watch and wait?—elevated pretreatment CEA Is associated with decreased pathological complete response in rectal cancer. J Gastrointest Surg. 2016;20:43–52.CrossRefPubMed
30.
Spindler KL. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. Acta Oncol. 2017;56(1):7–16.CrossRefPubMed
31.
Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6.CrossRefPubMedPubMedCentral
Metadata
Title
Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review
Authors
Anders Kindberg Boysen
Jakob Vasehus Schou
Karen-Lise Garm Spindler
Publication date
01-07-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1997-y

Other articles of this Issue 7/2019

Clinical and Translational Oncology 7/2019 Go to the issue

Research Article

Citron kinase (CIT-K) promotes aggressiveness and tumorigenesis of breast cancer cells in vitro and in vivo: preliminary study of the underlying mechanism

Research Article

The clinical significance of the alternative Wilms tumor gene overexpression–hypermethylation signature in acute myeloid leukemia

Research Article

Mortality of women with ductal carcinoma in situ of the breast: a population-based study from the Girona province, Spain (1994–2013)

Research Article

CEP55 promotes epithelial–mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway

Research Article

Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients

Research Article

Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits